Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma

被引：7
|
作者：
Miron, Benjamin [1 ]
Geynisman, Daniel M. [1 ]
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA USA
来源：
EUROPEAN UROLOGY | 2022年 / 82卷 / 04期
关键词：
CHEMOTHERAPY; CISPLATIN; MULTICENTER;
D O I：
10.1016/j.eururo.2022.05.023
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：374 / 376
页数：3
相关论文
共 50 条
  • [41] Trend in overall survival from the start of first-line chemotherapy in patients with metastatic urothelial carcinoma
    Yamamoto, Shoma
    Kato, Minoru
    Matsue, Taisuke
    Yukimatsu, Nao
    Takeyama, Yuji
    Otoshi, Taiyo
    Yamasaki, Takeshi
    Kuratsukuri, Katsuyuki
    Uchida, Junji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (02) : 221 - 224
  • [42] Bevacizumab - In first-line treatment of advanced and/or metastatic renal cell carcinoma
    Frampton, James E.
    Keating, Gillian M.
    BIODRUGS, 2008, 22 (02) : 113 - 120
  • [43] Optimal Number of Cycles of First-line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
    Minato, Akinori
    Ohno, Daichi
    Murooka, Kazuki
    Okumura, Yutaka
    Takaba, Tomohisa
    Higashijima, Katsuyoshi
    Nagata, Yujiro
    Tomisaki, Ikko
    Harada, Kenichi
    Fujimoto, Naohiro
    IN VIVO, 2024, 38 (04): : 1927 - 1934
  • [44] Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line Treatment
    Nikolaos Andreatos
    Patrick W. McGarrah
    Mohamad Bassam Sonbol
    Jason S. Starr
    Jaume Capdevila
    Halfdan Sorbye
    Thorvardur R. Halfdanarson
    Current Oncology Reports, 2023, 25 : 1127 - 1139
  • [45] Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma.
    Tural, Deniz
    Olmez, Omer Fatih
    Sumbul, Ahmet Taner
    Artac, Mehmet
    Ozhan, Nail
    Akar, Emre
    Cakar, Burcu
    Kostek, Osman
    Ekenel, Meltem
    Coskun, Hasan Senol
    Selcukbiricik, Fatih
    Keskin, Ozge
    Turkoz, Fatma Paksoy
    Oruc, Kerem
    Bayram, Selami
    Yilmaz, Ugur
    Bilgetekin, Irem
    Yildiz, Birol
    Sendur, Mehmet Ali Nahit
    Erman, Mustafa
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [46] Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line Treatment
    Andreatos, Nikolaos
    McGarrah, Patrick W. W.
    Sonbol, Mohamad Bassam
    Starr, Jason S. S.
    Capdevila, Jaume
    Sorbye, Halfdan
    Halfdanarson, Thorvardur R. R.
    CURRENT ONCOLOGY REPORTS, 2023, 25 (10) : 1127 - 1139
  • [47] BevacizumabIn First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma
    James E. Frampton
    Gillian M. Keating
    BioDrugs, 2008, 22 : 113 - 120
  • [48] Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladder
    Chakiryan, Nicholas H.
    Jiang, Da David
    Gillis, Kyle A.
    Green, Elizabeth
    Hajiran, Ali
    Hugar, Lee
    Zemp, Logan
    Zhang, Jingsong
    Jain, Rohit
    Chahoud, Jad
    Li, Roger
    Sexton, Wade
    Manley, Brandon J.
    Gilbert, Scott M.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (03) : 107.e11 - 107.e17
  • [49] The efficacy of axitinib as a first-line treatment for metastatic renal cell carcinoma
    Kameda, Tomohiro
    Takayama, Tatsuya
    Sugihara, Toru
    Takeshima, Saki
    Yamazaki, Masahiro
    Komatsubara, Maiko
    Kamei, Jun
    Fujisaki, Akira
    Ando, Satoshi
    Kurokawa, Shinsuke
    Fujimura, Tetsuya
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (04) : 241 - 246
  • [50] Cost-effectiveness of nivolumab plus gemcitabine-cisplatin as first-line treatment for advanced urothelial carcinoma in China and the United States
    Xiang, Guiyuan
    Huang, Yueyue
    Gan, Lanlan
    Wang, Linning
    Ding, Yunqi
    Wu, Yuanlin
    Xing, Haiyan
    Liu, Yao
    FRONTIERS IN IMMUNOLOGY, 2024, 15
12345